
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Barcelona - With a view on managing alopecia areata that is in complete contrast to the position commonly taken in the United States, Rudolf Happle, M.D., brings forward an interesting question: Why do dermatologists continue to use topical corticosteroids [and other treatments] if they are not truly effective in treating all forms of AA?